A new publication involving ganirelix was released on August 1, 2026. The article, titled "GnRH-receptor antagonism as a targeted approach to reproductive dysfunction in polycystic ovary syndrome," appears in the journal EBioMedicine. Ganirelix is an approved compound, and this publication discusses GnRH-receptor antagonism in the context of reproductive dysfunction associated with polycystic ovary syndrome. No specific findings, outcomes, or results from the publication have been provided beyond its title and placement in the journal. This entry reflects only the existence and bibliographic details of the publication as recorded. Readers interested in the full content and any reported findings should consult the original article directly through the source link. For additional context on ganirelix, including its approved uses and general background, see the compound overview.
Ganirelix Publication in EBioMedicine Examines PCOS Reproductive Dysfunction
See the full ganirelix overview
Source: https://pubmed.ncbi.nlm.nih.gov/42468113/